High-dose mitoxantrone with peripheral blood progenitor cell rescue
Author Information
Author(s): A Ballestrero, F Ferrando, A Garuti, P Basta, R Gonella, M Esposito, MO Vannozzi, G Sorice, D Friedman, M Puglisi, F Brema, GS Mela, M Sessarego, F Patrone
Primary Institution: Universita di Genova, Genoa, Italy
Hypothesis
Can high-dose mitoxantrone be safely administered with peripheral blood progenitor cell support?
Conclusion
High-dose mitoxantrone can be escalated up to 90 mg/m² with acceptable haematological toxicity when supported by peripheral blood progenitor cells.
Supporting Evidence
- Haematological recovery was rapid and complete at each NOV dose level without statistically significant differences.
- PBPCs can be safely reinfused as early as 96 hours after NOV administration.
- No treatment-related mortality was observed.
- High response rates were observed in both breast cancer and lymphoma patients.
Takeaway
This study shows that giving a strong cancer drug called mitoxantrone can be done safely in higher doses if doctors also give special cells to help the body recover.
Methodology
Thirty patients with breast cancer or non-Hodgkin's lymphoma received escalating doses of mitoxantrone with melphalan and peripheral blood progenitor cell rescue, with haematological toxicity evaluated daily.
Potential Biases
Potential bias in patient selection and reporting of outcomes.
Limitations
The study did not include a control group for comparison.
Participant Demographics
18 patients had metastatic breast cancer and 12 had non-Hodgkin's lymphoma, with a median age of 44 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website